Compugen Ltd. announced the appointment of three new members to its Board of Directors. Mr. Gilead Halevy, founding member and general partner of Kedma Capital Partners, Kinneret Livnat Savitzky, Ph.D., Interim CEO and board member of FutuRx Ltd., and Mr. Sanford (Sandy) Zweifach, founder and CEO of Nuvelution Pharma Inc. were appointed to Compugen's Board. These new board members fill vacancies and replace board members who have served on the Company's Board for many years. In addition to the recent resignation from the Board of Mr. Dov Hershberg announced last week, Ruth Arnon, Ph.D. and Michal Preminger, Ph.D., will not be brought for re-election at the next AGM. Gilead Halevy brings to Compugen extensive experience in complex cross-border transactions, deal making and finance. Mr. Halevy is a founding member and general partner of Kedma Capital Partners, since 2006. Dr. Kinneret Livnat Savitzky brings to Compugen significant experience in the life sciences industry, including drug discovery and development, corporate partnering and capital raising. Sanford Zweifach is senior executive with over 25 years' experience in the life sciences industry. He has an extensive background in corporate partnering, business development, operations, private and public investing, and capital raising.